Get started

Financials · DTIL

Precision BioSciences Inc. (DTIL) financials

For the twelve months ended Sep 30, 2026, Precision BioSciences Inc. reported $45.04M of revenue and -$38.55M of net income.

Revenue, TTM
$45.04M
Revenue growth, YoY
+6353.0%
Net income, TTM
-$38.55M
Net margin
-85.6%
Free cash flow, TTM
-$51.80M
Cash
$81.70M
P/S
6.00
Market cap
$270.4M
Annual revenue$34.26M
FY2018FY2025
Annual net income-$45.72M
FY2018FY2025
Annual free cash flow-$65.93M
FY2018FY2025

DTIL revenue and earnings growth

DTIL revenueQ3 2026$0

Quarter YoY
-100.0%
FY YoY
-50.1%
5Y CAGR
+7.1%

DTIL revenue was $0 in fiscal Q3 2026 (ended Sep 30, 2026), down 100.0% from a year earlier. For the full fiscal 2025 it was $34.26M, down 50.1% from fiscal 2024. Compound annual growth was +7.1% over 5 years. It rose in 5 of the last 7 fiscal years.

DTIL net incomeQ3 2026-$7.59M

DTIL net income was -$7.59M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$21.77M a year earlier. For the full fiscal 2025 it was -$45.72M, compared with $7.17M in fiscal 2024.

DTIL EPSQ3 2026-$0.28

DTIL diluted EPS was -$0.28 in fiscal Q3 2026 (ended Sep 30, 2026). For the full fiscal 2025 it was -$3.56.

DTIL free cash flowQ3 2026-$15.13M

DTIL free cash flow was -$15.13M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$15.27M a year earlier. For the full fiscal 2025 it was -$65.93M, compared with -$58.70M in fiscal 2024.

Export CSV

Income statement

Income statement
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue$34.26M$68.70M$48.73M$25.10M$115.53M$24.29M$22.24M$10.88M
Research and development$54.17M$59.56M$53.38M$46.12M$115.24M$98.06M$82.42M$45.12M
Selling, general and admin$32.24M$35.30M$39.09M$41.28M$39.67M$36.05M$27.03M$13.67M
Operating income-$52.15M-$26.16M-$43.74M-$62.31M-$39.38M-$109.83M-$87.20M-$47.91M
Interest expense$1.42M$1.78M$2.23M$1.11M$132.0K-$182.0K-
Pre-tax income-$45.72M$7.17M------
Income tax$0$0---$23.0K--
Net income-$45.72M$7.17M-$61.32M-$111.64M-$30.60M-$109.01M-$92.88M-$46.04M
EPS, basic-$3.56$1.05-$15.96-$38.10-$15.60-$62.70-$66.30-$87.60
EPS, diluted-$3.56$1.04-$15.96-$38.10-$15.60-$62.70-$66.30-$87.60
Diluted shares12.8M6.9M3.8M2.9M2.0M1.7M1.4M525,851.367

Balance sheet

Balance sheet
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Cash and equivalents$110.82M$108.47M$116.68M$189.58M$143.66M$89.80M$180.89M$103.19M
Short-term investments$4.76M$413.0K------
Receivables$0$229.0K$901.0K$720.0K$488.0K$10.00M$965.0K$523.0K
Current assets$118.74M$94.99M$136.36M$199.10M$161.75M$105.56M$193.67M$115.67M
Total assets$154.42M$136.39M$159.78M$238.17M$211.50M$150.16M$235.23M$138.60M
Current liabilities$8.91M$14.98M$49.99M$59.66M$35.98M$42.83M$26.93M$14.07M
Total debt---$22.22M$2.48M---
Total liabilities$62.17M$80.00M$140.92M$177.74M$120.33M$105.73M$96.92M$98.64M
Shareholders' equity$92.25M$56.39M$18.86M$60.43M$91.17M$44.42M$138.31M$39.96M

Cash flow

Cash flow
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Operating cash flow-$65.84M-$58.45M-$84.11M-$45.75M-$10.85M-$87.39M-$71.02M-$51.72M
Capital expenditures$85.0K$250.0K$1.96M$3.32M$5.05M$5.03M$24.67M$14.28M
Free cash flow-$65.93M-$58.70M-$86.07M-$49.07M-$15.91M-$92.42M-$95.68M-$66.00M
Investing cash flow-$634.0K-$215.0K$5.83M-$3.32M-$5.80M-$5.03M-$24.67M-$15.66M
Financing cash flow$95.16M$50.45M$5.39M$94.98M$70.52M$1.33M$173.37M$107.78M
Stock-based compensation$10.19M$12.60M$14.04M$19.20M$16.51M$13.79M$8.94M$2.45M
Depreciation and amortization$1.47M$3.40M$6.82M$7.80M$8.98M$8.78M$5.32M$2.35M

Key ratios

Key ratios
Line item
FY2025
Dec 31, 2025
FY2024
Dec 31, 2024
FY2023
Dec 31, 2023
FY2022
Dec 31, 2022
FY2021
Dec 31, 2021
FY2020
Dec 31, 2020
FY2019
Dec 31, 2019
FY2018
Dec 31, 2018
Revenue growth, YoY-50.1%41.0%94.1%-78.3%375.7%9.2%104.3%-
Operating margin-152.2%-38.1%-89.8%-248.3%-34.1%-452.2%-392.1%-440.2%
Net margin-133.4%10.4%-125.8%-444.8%-26.5%-448.9%-417.6%-423.0%
Free cash flow margin-192.4%-85.4%-176.6%-195.5%-13.8%-380.6%-430.3%-606.5%
Return on equity-49.6%12.7%-325.1%-184.7%-33.6%-245.4%-67.1%-115.2%
Return on assets-29.6%5.3%-38.4%-46.9%-14.5%-72.6%-39.5%-33.2%
Current ratio13.326.342.733.344.502.467.198.22
Debt to equity---0.370.03---

Source: XBRL data Precision BioSciences Inc. files with the SEC, latest filing dated Nov 3, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures and share counts are restated for stock splits the filings show: 1-for-30, first reported Mar 27, 2024.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

DTIL peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
DTIL$45.04M+6353.0%-$38.55M-85.6%$270.4M
AMGN$38.90B+8.2%$9.39B24.1%$251.65B
GILD$30.99B+6.5%-$3.86B-12.5%$210.01B
MRNA$2.52B+13.1%-$2.79B-110.5%$107.39B
ARGX$4.25B+88.6%$1.29B30.4%$59.72B
RVMD$0--$1.13B-$43.29B
BIIB$10.30B+2.3%$347.50M3.4%$37.67B
BNTX€2.87B+4.3%-€1.14B-39.6%$21.98B
EXEL$2.50B+9.1%$885.14M35.5%$17.51B

DTIL FAQ

7 questions
  • What is DTIL revenue?
    Precision BioSciences Inc. (DTIL) reported $45.04M of revenue for the twelve months ended Sep 30, 2026. That is up 6353.0% from the year before. Revenue for fiscal 2025 was $34.26M.
  • Is DTIL profitable?
    No. Precision BioSciences Inc. reported a net loss of $38.55M for the twelve months ended Sep 30, 2026.
  • How much cash and debt does DTIL have?
    Precision BioSciences Inc. reported $81.70M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is DTIL revenue growing?
    Precision BioSciences Inc.'s revenue changed -50.1% in fiscal 2025, to $34.26M. Its compound annual growth rate was +7.1% over 5 years.
  • What is DTIL free cash flow?
    Precision BioSciences Inc. generated -$51.80M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$51.76M less capital expenditures.
  • When did DTIL last report financial results?
    The latest statements here come from Precision BioSciences Inc.'s 10-Q filed on Nov 3, 2026, covering the period ended Sep 30, 2026.
  • Where does this DTIL financial data come from?
    Quantisnow builds these statements from the structured XBRL data Precision BioSciences Inc. files with the SEC. It is provided for information only and is not investment advice.